- A 59-year-old woman has invasive ductal carcinoma treated with lumpectomy and sentinel node biopsy. Pathology shows a 2.8-cm tumor, 1/3 sentinel nodes positive with a small metastasis; she will receive whole-breast radiation. She asks if she needs a full axillary dissection. The surgeon explains that in select patients with limited sentinel node involvement undergoing breast-conserving surgery with radiation, completion axillary dissection may be omitted to reduce lymphedema risk, consistent with modern guideline-based practice.
Which of the following is the most appropriate next step in management for this patient?
Answer: Omit completion axillary dissection and proceed with planned adjuvant radiation therapy
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest limited sentinel node positivity in a patient receiving lumpectomy and radiation, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending omission of completion axillary dissection in select cases to reduce lymphedema risk. Choice B is incorrect because it represents overtreatment with dissection, which often arises from not applying modern trial data like Z0011. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
- A 32-year-old woman presents with a 5-cm left breast mass fixed to pectoralis muscle and clinically palpable axillary nodes. Core biopsy confirms triple-negative invasive ductal carcinoma. She desires breast conservation if possible. What is the most appropriate initial management?
Answer: Initiate neoadjuvant multi-agent chemotherapy before surgical resection
When you encounter locally advanced breast cancer (T3/T4 tumors), the key decision point is whether neoadjuvant therapy can downstage the tumor to allow for better surgical outcomes and breast conservation.
This patient has a 5-cm mass fixed to the pectoralis muscle, making it at least T4a (locally advanced). The triple-negative histology is actually favorable for neoadjuvant chemotherapy, as these tumors are typically chemosensitive and can achieve significant pathologic responses. Since she desires breast conservation, neoadjuvant multi-agent chemotherapy (option A) is the most appropriate first step to potentially shrink the tumor and convert an inoperable or marginally operable case into one amenable to breast-conserving surgery.
Option B (modified radical mastectomy) ignores the patient's preference for breast conservation and doesn't address the locally advanced nature that may benefit from systemic therapy first. Option C (immediate lumpectomy) is inappropriate because the 5-cm tumor fixed to muscle would likely have positive margins and poor cosmetic outcomes without downstaging. Option D (endocrine therapy) is incorrect because this is triple-negative breast cancer, meaning it lacks estrogen and progesterone receptors, making it unresponsive to hormonal manipulation.
Remember this pattern: For locally advanced breast cancer where the patient desires breast conservation, neoadjuvant chemotherapy is often the bridge between an initially unresectable/poor surgical candidate and successful breast-conserving therapy. Triple-negative tumors respond particularly well to neoadjuvant chemotherapy, making this approach even more compelling.
- A 50-year-old woman treated with lumpectomy and sentinel lymph node biopsy for a 2.4-cm ER-negative, PR-negative, HER2-negative tumor received adjuvant radiation and chemotherapy. She now has chronic right-arm lymphedema. Which intervention provides the best evidence-based long-term improvement of limb volume?
Answer: Daily physician-guided complex decongestive therapy with compression garments
When you encounter lymphedema management questions, focus on evidence-based interventions that address the underlying pathophysiology of impaired lymphatic drainage and fluid accumulation.
Post-mastectomy lymphedema requires comprehensive treatment targeting both immediate decongestive therapy and long-term volume maintenance. Complex decongestive therapy (CDT) represents the gold standard, combining manual lymphatic drainage, compression bandaging, therapeutic exercises, and skin care. The "physician-guided" aspect in option A ensures proper technique and monitoring. Compression garments provide sustained pressure to prevent re-accumulation of lymphatic fluid, making this the most evidence-supported approach for long-term volume reduction.
Option B (prophylactic antibiotics) addresses infection prevention but doesn't treat the underlying lymphedema. While cellulitis can worsen lymphedema, antibiotics alone won't improve limb volume and aren't routinely recommended for lymphedema prevention.
Option C (intermittent pneumatic compression only at night) provides some benefit but is insufficient as monotherapy. Without the comprehensive approach of CDT, including manual drainage and daytime compression, results are suboptimal for long-term volume control.
Option D (early debulking liposuction without conservative therapy) is premature and inappropriate. Liposuction is reserved for refractory cases after conservative management has failed, and even then, it requires post-operative compression therapy for success.
USMLE Strategy: Lymphedema questions often test whether you know that comprehensive conservative therapy (CDT with compression) is first-line treatment. Surgical interventions are last resort, and isolated therapies rarely provide optimal outcomes compared to multimodal approaches.
- A 52-year-old woman presents with unilateral eczematous changes of the left nipple for 4 months. She reports itching and occasional serous discharge. Topical steroids provided minimal relief. She has no fevers. Exam shows erythema and scaling of the nipple-areolar complex with slight crusting; a subtle subareolar firmness is appreciated. No axillary nodes are palpable. Diagnostic mammography shows microcalcifications beneath the nipple. Punch biopsy of the nipple shows malignant cells within the epidermis consistent with Paget disease. The clinician explains that this finding is usually associated with underlying DCIS or invasive carcinoma and requires breast imaging and definitive surgical management.
Which of the following is the most likely diagnosis given the patient's presentation and test results?
Answer: Paget disease of the breast associated with underlying ductal carcinoma
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest Paget disease with underlying carcinoma confirmed by biopsy, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending evaluation for associated DCIS or invasive disease requiring surgical management. Choice B is incorrect because it represents undertreatment with topical therapy, which often arises from confusing malignant with benign dermatologic conditions. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
- A 46-year-old woman presents with a palpable breast mass. She has dense breasts on prior imaging and is worried that mammography will miss cancer. Exam shows a 2-cm firm mass; no skin changes. She has no contraindications to imaging. The clinician explains that for women ≥40 with a palpable mass, diagnostic mammography is first-line, often combined with targeted ultrasound; breast MRI is reserved for specific indications such as high-risk screening, problem-solving, or staging in selected cases, not as initial test for most palpable masses.
What is the most appropriate initial diagnostic test for this patient's breast mass?
Answer: Diagnostic mammography with targeted ultrasound of the palpable region
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest a palpable mass in a woman with dense breasts requiring initial evaluation, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending diagnostic mammography with targeted ultrasound as first-line for palpable masses in women ≥40. Choice B is incorrect because it represents misuse of MRI as initial test, which often arises from overestimating its role in routine diagnostics. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
- A 45-year-old woman undergoes excisional biopsy for a 2.1-cm invasive ductal carcinoma in the upper-outer quadrant of the left breast. Pathology shows estrogen-receptor positive, progesterone-receptor positive, HER2-negative disease with clear surgical margins (>2 mm). Sentinel lymph node biopsy is negative. The patient has no comorbidities and wishes to preserve her breast. What is the most appropriate next step in management?
Answer: Schedule whole-breast external-beam radiation therapy followed by endocrine treatment
When you encounter early-stage breast cancer questions on Step 2, focus on the breast conservation pathway and understand that successful lumpectomy with clear margins requires adjuvant radiation to achieve outcomes equivalent to mastectomy.
This patient has early-stage invasive ductal carcinoma (T1c, N0, M0) with hormone receptor-positive, HER2-negative disease. She's an ideal candidate for breast-conserving therapy since she has a small tumor relative to breast size, clear surgical margins, negative nodes, and desires breast preservation. The standard of care after successful lumpectomy is whole-breast radiation therapy followed by endocrine therapy (tamoxifen or an aromatase inhibitor) for her hormone receptor-positive disease. This approach provides local control equivalent to mastectomy while preserving the breast.
Choice B is incorrect because chemotherapy isn't typically indicated for small, node-negative, hormone receptor-positive tumors unless high-risk features are present or genomic testing suggests benefit. Choice C fails because observation alone after lumpectomy leads to unacceptably high local recurrence rates (around 30-40% at 10 years without radiation). Choice D represents overtreatment since breast conservation with radiation achieves equivalent survival outcomes to mastectomy for early-stage disease.
Key Step 2 strategy: Remember the breast conservation trinity - appropriate candidate selection, negative surgical margins, and adjuvant radiation therapy. When all three elements are present, breast-conserving therapy is preferred over mastectomy. Always consider the patient's preferences when equivalent treatment options exist, but don't compromise oncologic principles.
- A 54-year-old woman has a screening mammogram that reveals clustered microcalcifications in the right breast. Core needle biopsy shows high-grade ductal carcinoma in situ (DCIS). She chooses lumpectomy. Sentinel lymph nodes are negative and margins are clear. Which adjuvant therapy most reduces the risk of ipsilateral breast recurrence in this setting?
Answer: Whole-breast radiation after lumpectomy
When you encounter high-grade DCIS treated with lumpectomy, think about local recurrence prevention. DCIS is a pre-invasive lesion confined to breast ducts, but it has significant potential for local recurrence, which can be either DCIS again or invasive cancer.
A) Whole-breast radiation is correct because multiple randomized trials (NSABP B-17, EORTC 10853) have consistently shown that radiation therapy after lumpectomy reduces ipsilateral breast recurrence by approximately 50-60% in DCIS patients. This benefit applies to both DCIS recurrence and progression to invasive cancer. Radiation addresses microscopic disease that may remain in the breast despite clear margins.
B) Anthracycline-based chemotherapy is used for invasive breast cancer with high recurrence risk, but DCIS hasn't invaded beyond the basement membrane. Chemotherapy targets systemic micrometastases, which don't exist in pure DCIS, making this inappropriate and unnecessarily toxic.
C) Aromatase inhibitor monotherapy isn't standard for DCIS. While tamoxifen has shown modest benefit in hormone receptor-positive DCIS, aromatase inhibitors alone aren't the primary adjuvant therapy and don't address the full spectrum of DCIS biology as effectively as radiation.
D) No additional therapy ignores substantial evidence that DCIS recurrence rates are unacceptably high (15-20% at 10 years) without radiation, and roughly half of recurrences are invasive cancer.
Study tip: For DCIS management questions, remember that radiation after lumpectomy is the gold standard for reducing local recurrence. The key distinction is local control (radiation) versus systemic therapy (chemotherapy/hormones), which isn't needed for non-invasive disease.
- A 59-year-old man notes a 1.8-cm firm, nontender subareolar mass beneath the right nipple. Core biopsy confirms invasive ductal carcinoma that is estrogen-receptor positive and HER2-negative. Imaging shows no distant disease. What is the most appropriate surgical treatment?
Answer: Total (simple) mastectomy with sentinel lymph node biopsy
When you encounter male breast cancer on the USMLE Step 2, remember that while rare (accounting for <1% of all breast cancers), the surgical principles largely mirror female breast cancer treatment, with one crucial difference: breast conservation is rarely feasible due to limited breast tissue.
Total mastectomy with sentinel lymph node biopsy (Answer A) is correct because men have minimal breast tissue, making it nearly impossible to achieve adequate margins while preserving cosmetically acceptable tissue. The 1.8-cm subareolar mass would require removing most or all of the breast tissue anyway. Sentinel lymph node biopsy is the standard staging procedure for clinically node-negative breast cancer, regardless of gender.
Answer B (wide local excision with radiation) represents the standard breast-conserving approach used in women, but this is impractical in men due to the small amount of breast tissue and subareolar location of most male breast cancers.
Answer C (radical mastectomy) is outdated and unnecessarily morbid. Radical mastectomy, which removes the pectoralis muscles, was abandoned decades ago when studies showed that total mastectomy with lymph node assessment provides equivalent survival with much less morbidity.
Answer D (excision only) ignores the need for lymph node staging, which is essential for determining prognosis and adjuvant therapy decisions. Simply removing the mass without assessing nodal status would be inadequate cancer treatment.
Key takeaway: Male breast cancer treatment defaults to mastectomy due to anatomical constraints, but follows the same staging principles as female breast cancer, including sentinel lymph node biopsy for appropriate patients.
- A 60-year-old woman with newly diagnosed breast cancer has a 2.2-cm invasive ductal carcinoma, ER/PR positive, HER2 negative. She is clinically node-negative. She is scheduled for lumpectomy and sentinel lymph node biopsy. She asks what happens if the sentinel nodes are negative. The surgeon explains that sentinel lymph node biopsy is the standard staging procedure for clinically node-negative disease and avoids morbidity of full axillary dissection; if sentinel nodes are negative, no further axillary surgery is indicated. If limited sentinel node positivity is found in select patients receiving breast-conserving therapy and radiation, axillary dissection may still be avoided.
Which of the following is most aligned with current clinical guidelines for this condition?
Answer: Perform sentinel lymph node biopsy; if negative, omit further axillary surgery
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest clinically node-negative invasive carcinoma requiring axillary staging, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending sentinel lymph node biopsy, omitting further surgery if negative to minimize morbidity. Choice B is incorrect because it represents overtreatment with routine dissection, which often arises from outdated practices predating sentinel node techniques. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
- A 55-year-old woman underwent lumpectomy and sentinel lymph node biopsy 3 weeks ago for a 1.6-cm invasive ductal carcinoma. Pathology shows clear margins, 0/2 sentinel nodes involved, ER/PR positive, HER2 negative, grade 2. She is recovering well and has no wound complications. She asks what follow-up and adjuvant care she needs to reduce recurrence risk. The surgeon reviews that breast-conserving therapy includes whole-breast radiation after lumpectomy, and ER-positive disease typically receives adjuvant endocrine therapy. Surveillance includes regular history/physical and annual mammography; routine PET/CT or tumor markers are not recommended in asymptomatic patients.
What is the most suitable follow-up plan post-surgery?
Answer: Annual mammography plus adjuvant whole-breast radiation and endocrine therapy
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest early-stage ER-positive breast cancer post-lumpectomy with negative nodes, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending annual mammography, whole-breast radiation, and endocrine therapy for surveillance and risk reduction. Choice B is incorrect because it represents overuse of advanced imaging, which often arises from anxiety-driven misconceptions about detecting asymptomatic metastases. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
- A 44-year-old woman presents with a palpable breast mass. She has a strong family history: mother with ovarian cancer at 49 and maternal aunt with breast cancer at 42. Exam reveals a 2-cm irregular mass; no skin changes. Diagnostic mammography and ultrasound are suspicious. Core biopsy confirms invasive ductal carcinoma. She asks about genetic testing and how it affects surgical planning. Current recommendations support genetic counseling/testing for patients with early-onset breast cancer and suggest that results may influence consideration of bilateral mastectomy and risk-reducing salpingo-oophorectomy in BRCA carriers.
Which of the following is the most appropriate next step in management for this patient?
Answer: Refer for genetic counseling and germline testing to guide surgical risk-reduction decisions
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest early-onset breast cancer with strong family history warranting genetic evaluation, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending genetic counseling and testing to inform risk-reduction strategies like bilateral mastectomy in carriers. Choice B is incorrect because it represents underutilization of genetics, which often arises from underestimating its impact on surgical decisions. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
- A 48-year-old woman undergoes segmental mastectomy for a 3-cm invasive lobular carcinoma. Final pathology reveals tumor extending to the inked margin on the deep surface. Sentinel nodes are negative. Which option is the most appropriate next step?
Answer: Return to the operating room for re-excision of the involved margin
When you encounter breast cancer surgery complications, always consider the adequacy of surgical margins first. Clear margins are crucial for local control, and positive margins significantly increase the risk of local recurrence.
In this case, the patient has a positive deep margin after segmental mastectomy (breast-conserving surgery). The standard of care requires achieving negative margins, typically defined as no tumor cells within 2mm of the inked surgical margin. Since the sentinel nodes are negative, indicating no nodal involvement, the focus should be on achieving local control through complete surgical excision.
Option A is correct because re-excision of the involved deep margin is the standard approach for positive margins after breast-conserving surgery. This allows for complete tumor removal while preserving the breast, which was the patient's initial surgical choice.
Option B is incorrect because proceeding directly to radiation with known positive margins provides inadequate local control. Radiation cannot reliably sterilize gross residual disease at surgical margins.
Option C represents a fundamental misunderstanding of neoadjuvant versus adjuvant therapy. Neoadjuvant chemotherapy is given before surgery to downsize tumors, not after surgery to address margin issues. Additionally, chemotherapy doesn't reliably clear microscopic disease at surgical margins.
Option D (completion mastectomy) is unnecessarily aggressive since the margin issue can likely be addressed with re-excision. Axillary lymph node dissection is also inappropriate given negative sentinel nodes.
Key takeaway: For positive margins after breast-conserving surgery, always attempt re-excision first before considering more aggressive interventions like mastectomy. Clear surgical margins are the foundation of local cancer control.
- A 70-year-old woman presents with a new right breast mass. She has COPD and chronic kidney disease stage 3. Exam shows a 3-cm firm mass with skin tethering and palpable axillary nodes. Core biopsy confirms invasive ductal carcinoma, HER2 positive, ER negative. Echocardiogram shows normal LVEF. She asks about treatment sequencing. The oncologist explains that HER2-positive tumors often benefit from neoadjuvant chemotherapy plus HER2-targeted therapy to downstage disease and improve surgical options; surgery follows with appropriate axillary staging and radiation based on surgical approach.
Which treatment option is most aligned with current clinical guidelines for this condition?
Answer: Neoadjuvant chemotherapy with HER2-targeted therapy followed by definitive breast surgery
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest locally advanced HER2-positive breast cancer suitable for neoadjuvant therapy, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending neoadjuvant chemotherapy with HER2-targeted agents to downstage disease before surgery. Choice C is incorrect because it represents incorrect sequencing, which often arises from underestimating systemic therapy's role in HER2-positive disease. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
- A 55-year-old woman with newly diagnosed inflammatory breast carcinoma involving two-thirds of the left breast asks about immediate mastectomy. Which statement best explains why surgery is not the first therapeutic step?
Answer: Systemic chemotherapy must precede surgery to improve survival and permit resectability
Inflammatory breast cancer (IBC) is an aggressive form of breast cancer that presents unique management challenges. When you encounter IBC questions, remember that this cancer behaves differently from typical breast cancers due to its rapid growth, extensive skin involvement, and high likelihood of micrometastatic disease at diagnosis.
The correct approach is A - systemic chemotherapy must precede surgery. IBC is characterized by dermal lymphatic invasion causing the classic "peau d'orange" appearance and rapid progression. At diagnosis, micrometastases are almost always present, making this a systemic disease requiring systemic treatment first. Neoadjuvant chemotherapy serves two critical purposes: it addresses the presumed micrometastatic disease to improve survival, and it shrinks the extensive local tumor burden to make surgical resection technically feasible and more likely to achieve clear margins.
B is incorrect because radiation therapy alone cannot cure IBC - this aggressive cancer requires multimodal therapy including chemotherapy, surgery, and radiation. C misses the point entirely; while lymphedema is a concern with axillary dissection, it's not the reason to delay surgery in IBC. The delay is about disease biology, not surgical complications. D is wrong because even though many breast cancers are ER-positive, hormone therapy alone is insufficient for IBC regardless of receptor status - the aggressive nature demands more intensive treatment.
Key takeaway: For USMLE Step 2, remember that IBC is always treated with neoadjuvant chemotherapy first, regardless of stage, because it's considered systemic disease at diagnosis. This distinguishes it from most other breast cancers where surgery might be the initial treatment.
- A 53-year-old woman underwent mastectomy for a 4.8-cm invasive ductal carcinoma with 4/15 axillary nodes positive. Margins are negative. Tumor is ER positive, HER2 negative. She asks whether she needs radiation despite mastectomy. The clinician explains that postmastectomy radiation is recommended for patients with high-risk features such as ≥4 positive nodes or large tumors, as it reduces locoregional recurrence and improves outcomes; endocrine therapy is also indicated for ER-positive disease.
Which treatment option is most aligned with current clinical guidelines for this condition?
Answer: Postmastectomy chest wall and regional nodal radiation plus adjuvant systemic therapy
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest high-risk features post-mastectomy with multiple positive nodes, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending postmastectomy radiation to chest wall and nodes plus adjuvant systemic therapy to reduce recurrence. Choice B is incorrect because it represents undertreatment by omitting radiation, which often arises from overemphasizing negative margins alone. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
- A 38-year-old woman who is 24 weeks pregnant presents with a new left breast lump for 2 weeks. She denies fever or nipple discharge. She has no prior breast imaging. Exam shows a 2-cm firm mass without overlying erythema; no axillary nodes are palpable. She is concerned about fetal radiation exposure. The clinician explains that evaluation of a palpable mass in pregnancy begins with breast ultrasound, which is safe and can guide biopsy if suspicious; diagnostic mammography with abdominal shielding may be added if needed.
What is the most appropriate initial diagnostic test for this patient's breast mass?
Answer: Targeted breast ultrasound of the palpable area
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest a palpable mass during pregnancy requiring safe evaluation, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending targeted ultrasound as the initial test in pregnancy to avoid fetal radiation exposure. Choice C is incorrect because it represents inappropriate use of contrast agents, which often arises from ignoring pregnancy-specific safety concerns. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
- A 43-year-old woman presents with eczematous changes of the right nipple and intermittent bloody discharge. Physical exam reveals no palpable mass. Mammography is negative. Punch biopsy of the nipple demonstrates large malignant cells within the epidermis, positive for HER2. What is the most appropriate initial imaging or diagnostic step to determine the extent of underlying malignancy?
Answer: Contrast-enhanced breast MRI to detect occult invasive disease
This question tests your understanding of Paget disease of the breast, a rare form of breast cancer that presents with eczematous nipple changes and represents underlying ductal carcinoma in situ (DCIS) or invasive carcinoma.
When you encounter eczematous nipple changes with bloody discharge and biopsy showing malignant cells in the epidermis (characteristic of Paget disease), your priority is determining whether there's underlying invasive disease that isn't clinically apparent. Since mammography was negative and no mass is palpable, contrast-enhanced breast MRI becomes essential. MRI has superior sensitivity for detecting occult invasive carcinoma associated with Paget disease, which occurs in 80-90% of cases. This information is crucial for surgical planning and determining whether mastectomy or breast-conserving surgery is appropriate.
Choice B (PET-CT) is premature because you haven't yet established the local extent of disease or confirmed invasion. Systemic staging comes after determining local disease characteristics. Choice C (ultrasound-guided axillary biopsy) is incorrect because you don't randomly biopsy lymph nodes without first confirming invasive disease and identifying specific suspicious nodes. Choice D (bone scan) is also premature staging - you need to establish the primary tumor extent before looking for distant metastases.
Remember this pattern: In Paget disease of the breast, after confirming the diagnosis histologically, your next step is always breast MRI to evaluate for occult invasive disease. Don't jump to staging procedures until you've fully characterized the primary tumor's extent and invasiveness.
- A 29-year-old woman is in her second trimester (22 weeks' gestation) when she discovers a 2-cm palpable mass in the left breast. Ultrasound-guided core biopsy reveals grade 3 invasive ductal carcinoma, ER-negative, PR-negative, HER2-negative. Staging studies show no metastases. What is the most appropriate immediate management?
Answer: Begin neoadjuvant anthracycline-based chemotherapy during pregnancy
Pregnancy-associated breast cancer requires balancing maternal oncologic outcomes with fetal safety. When you encounter breast cancer in pregnancy, remember that delays in treatment worsen maternal prognosis, but many chemotherapy agents can be safely administered during the second and third trimesters.
This patient has triple-negative breast cancer (TNBC), an aggressive subtype that requires prompt systemic therapy. Anthracycline-based chemotherapy (like doxorubicin and cyclophosphamide) is considered safe after the first trimester because organogenesis is complete by 10-12 weeks. Studies show no increased risk of congenital malformations, growth restriction, or developmental delays when these agents are given after 14 weeks gestation.
Option A is correct because immediate neoadjuvant chemotherapy addresses the aggressive tumor while maintaining the pregnancy safely in the second trimester.
Option B is incorrect because termination isn't medically necessary for maternal treatment, and elective termination doesn't improve oncologic outcomes compared to continuing pregnancy with appropriate chemotherapy.
Option C is wrong because delaying treatment for 18+ weeks significantly worsens prognosis in TNBC. The aggressive nature of triple-negative tumors makes prompt treatment essential, and the delay could allow progression to advanced disease.
Option D represents inappropriate management because therapeutic termination isn't indicated when safe treatment options exist, and combining termination with mastectomy in one operation isn't standard practice.
Remember: After the first trimester, most standard chemotherapy regimens can be safely administered during pregnancy. The key is avoiding teratogenic agents and timing delivery appropriately around treatment cycles.
- A 66-year-old woman presents with progressive right breast skin thickening and redness for 3 weeks. She was treated with oral antibiotics for presumed mastitis without improvement. She denies breastfeeding and has no fever. Exam shows diffuse erythema involving more than one-third of the breast with peau d'orange and a poorly defined underlying firmness; ipsilateral axillary nodes are palpable. Diagnostic mammography and ultrasound show skin thickening and an ill-defined mass. Core biopsy confirms invasive carcinoma with dermal lymphatic invasion. The team discusses that inflammatory breast cancer is aggressive and typically managed with neoadjuvant systemic therapy followed by mastectomy and radiation, not upfront lumpectomy.
Which of the following is the most likely diagnosis given the patient's presentation and test results?
Answer: Inflammatory breast cancer requiring neoadjuvant therapy and multimodal treatment
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest inflammatory breast cancer with failed antibiotic response and biopsy confirmation, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending neoadjuvant therapy followed by mastectomy and radiation for this aggressive subtype. Choice B is incorrect because it represents diagnostic delay, which often arises from misattributing symptoms to infection despite lack of improvement. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
- A 57-year-old woman presents with back pain and fatigue 6 years after treatment of ER-positive breast cancer with lumpectomy, radiation, and 5 years of endocrine therapy. She reports new mid-thoracic pain worse at night. Exam shows mild tenderness over the thoracic spine but no neurologic deficits. Labs reveal elevated alkaline phosphatase and normal calcium. She has no breast mass on exam. Given concern for metastatic recurrence, the clinician explains that evaluation typically includes imaging for bone metastases and staging studies; management of metastatic ER-positive disease often includes systemic endocrine therapy with targeted agents, with local therapy for symptom control.
Which of the following is the most appropriate next step in management for this patient?
Answer: Obtain imaging for suspected bone metastases, such as bone scan or PET/CT
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest possible bone metastases with elevated alkaline phosphatase years post-treatment, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending bone scan or PET/CT for symptomatic evaluation in suspected recurrence. Choice B is incorrect because it represents diagnostic omission, which often arises from attributing symptoms to benign causes without investigation. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
